fda semaglutide warning US removes suicidal thoughts from weight-loss drugs The FDA sent a warning

Federal law permits 503A state-licensed compounding pharmacies and 503B outsourcing facilities to compound medications during active shortage periods

SGLT2 inhibitors (e.g., dapagliflozin, canagliflozin, and empagliflozin) and glucagon-like peptide-1 receptor agonists (GLP1-RAs

This characteristic means even systemic injections into abdominal fat can support healing throughout the body

Intended for use within controlled laboratory environments

However, significant challenges persist, including concerns related to immunogenicity, limited reproducibility, high manufacturing costs, and the lack of validated clinical biomarkers for therapeutic response